May 25,2016

Medisafe Presents Results of Six-Month Medication Adherence Improvement Study at ISPOR 2016

Medisafe, the personalized medication management platform with over 2.8 million users, announced today that findings from a scientific study conducted by IMS Health showing Medisafe’s medication adherence benefits will be presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting in Washington D.C. The study showed that Medisafe users taking cholesterol and hypertension medication had 19.5% and 8.4% higher relative adherence at six months respectively compared to a control group of non-users.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Aug 28,2023

New Woebot Health Study Highlights AI's Ability to Address Equity and Accessibility Gaps in Mental Health Care

Woebot Health today announced the results from a new study of Woebot for Adults (previously Woebot-LIFE), a digital mental health intervention that provides in-the-moment support to people experiencing symptoms of anxiety and depression. The study, in which 256 adults received an 8-week intervention, was designed to assess changes in depression and anxiety symptoms, stress, resilience, burnout, levels of engagement and therapeutic working alliance, as well as access and barriers to care. Key study findings showed that participants with baseline clinical levels of depressive or anxiety symptoms experienced significant declines in self-reported symptoms. Woebot for Adults is a non-prescription medical device under FDA enforcement discretion; it is not evaluated, cleared or approved by FDA. Robinson added the study will periodically relaunch to collect new data and new insights as part of the company’s “Science in the Loop” approach to product development.

CLINICAL STUDY

#chatbot

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 11,2023 TOP STORY

Nemaura Medical Completes 100 Patient Study for sugarBEAT® 24-hour Wear and Reports Interim Results

Nemaura Medical , a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized diabetes management and metabolic health programs, today announced it has recently completed a 100-patient study across 4 cohorts of 25 diabetic patients for sugarBEAT® and provided interim results. This study was designed to evaluate several factors, including the possibility of increasing the wear period to up to 24 hours, evaluating the possibility of auto-calibration, and different methods of application of the device to the skin. The study was conducted in the Middle East on 100 adult patients aged 18 to 75 comprising 20 persons with Type 1 diabetes and 80 persons with Type 2 diabetes. The Company reports interim data from a first cohort comprising 25 patients, on a single day sensor wear. The results indicate that a 24-hour sensor wear period using a single sensor is possible, which is expected to allow users to monitor their glucose fluctuations overnight.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 13,2023

Nemaura Medical Announces Interim Results from its Collaboration with the UK’s National Health Service on its Metabolic Health & Weight Loss Program

Nemaura Medical, a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced interim results from its metabolic health program. The primary objective of the study was to establish whether a metabolic program with a daily wear CGM worn twice a month resulted in greater engagement levels and sustainable weight reduction, and how this compared to other programs. The multi-centered study was run in collaboration with the UK’s National Health Service. Known as Miboko (Mind, Body, Konnect), the program is the first to integrate a daily-wear and non-invasive glucose sensor with the Company’s bespoke app, educational content and AI driven analytics platform. Qualitative feedback from users demonstrated substantially increased levels of understanding and empowerment on their weight loss goals, correlating to long-term behavioural changes that are pivotal to sustained weight loss. After 20 weeks of use, the program had a retention rate of 32.5%. When active participants were asked whether they would continue with the program, 64% of respondents stated they were likely or very likely to continue to use the program. The Company plans to publish more detailed results in due course.

CLINICAL STUDY

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Aug 01,2017

Evaluation of a Digital Behavioral Counseling Program for Reducing Risk Factors for Chronic Disease in a Workforce

The aim of the study from Omada Health is to evaluate a digitally delivered, intensive behavioral counseling program for a workforce at risk for obesity-related chronic disease. Employees were offered a digital health program modeled after the diabetes prevention program (DPP). Annual workforce health assessments were used to examine changes in chronic disease risk factors between participants (n = 634) relative to a matched comparison group (n = 1268). Overall, employees were gaining an average of 3.5 pounds annually before program inception. Program engagement was positive; 83% completed the majority of the curriculum and 31% lost at least 5% of their starting weight. Compared with non-participating peers, participants demonstrated reduced weight, improved fasting blood glucose, and improved nutritional intake after a year.

CLINICAL STUDY

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Aug 01,2023

Implementation of flash glucose monitoring in four pediatric diabetes clinics: controlled before and after study to produce real-world evidence of patient benefit

The aim of this study is to assess the real-world evidence for flash glucose monitoring (Abbott FreeStyle Libre) for children with type 1 diabetes in terms of glucose control, secondary healthcare resources and costs. The researchers conducted a controlled before and after study (approximately 12?months before and after) using routinely collected health record data on children who start using flash monitors and a control population of children with self-monitoring of blood glucose (SMBG). Outcome measures included: glycated hemoglobin (HbA1c), frequency of BG tests; frequency of sensor scans; time in recommended glucose range; short-term complications (hypoglycemia, diabetic ketoacidosis and related illness resulting in investigation) and secondary care costs. In terms of the results, there was some indication that flash monitoring might help young people improve the control of their diabetes but for the sutdy sample, the difference between finger-prick testing and flash monitoring was not clinically significant (HbA1c improvement <5 mmol/mol). Given the pace of technological change within diabetes, they suggest that research offerts should now facilitate the real-time analysis of long-term routine data on flash and continuous glucose monitors.

CLINICAL STUDY

#cgm

#bgm

View Analyst & Ambassador Comments
Go to original news
Aug 25,2023

ChatGPT Shows Limited Ability to Recommend Guidelines-Based Cancer Treatments

With ChatGPT now at patients’ fingertips, researchers from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, assessed how consistently the artificial intelligence chatbot provides recommendations for cancer treatment that align with National Comprehensive Cancer Network (NCCN) guidelines. Their findings, published in JAMA Oncology, show that in approximately one-third of cases, ChatGPT 3.5 provided an inappropriate (“non-concordant”) recommendation, highlighting the need for awareness of the technology’s limitations.

CLINICAL STUDY

#chatbot

#ai/software

View Analyst & Ambassador Comments
Go to original news
Aug 22,2023

UK study prompts call for MRI screening for prostate cancer

A UK study has suggested that a 10-minute MRI scan is more effective at detecting prostate cancer than testing for blood levels of the biomarker PSA, picking up serious cases that would not be spotted using PSA alone. There is currently no UK-wide screening programme for prostate cancer because the PSA test is not reliable, although men aged over 50 can request one if desired. The analysis revealed that out of 29 who were found to have serious prostate cancer, 15 had a low PSA score, which would mean they were not referred for further clinical investigation. Three men were diagnosed with low-risk cancer that did not require treatment.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Aug 22,2023

Veracyte Announces that Findings Published in JCO Precision Oncology to Predict Treatment Response in Recurrent Prostate Cancer

Veracyte announced that new data published in JCO Precision Oncology suggest that gene expression signatures derived from the company’s Decipher Genomics Resource for Intelligent Discovery (GRID) database may help advance understanding of the genomic drivers impacting patient response to treatment for recurrent prostate cancer. Researchers conducted a retrospective analysis using the Decipher GRID database to determine whether specific genomic signatures could help predict which patients would benefit from the aggressive therapy regimen, and which may require additional or alternative care. The findings, from the Phase 2 STREAM study, suggest the potential to use transcriptomic signatures to identify patients in this setting who may benefit from more intensive salvage therapy as well as those who may need alternative care such as chemotherapy.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jul 17,2023

Association Between Diabetes Technology Use and Glycemic Outcomes in Adults With Type 1 Diabetes Over a Decade

The objective of this study was to assess how the use of diabetes technology in adults with type 1 diabetes impacted the average clinic-measured HbA1c levels from 2014 to 2021. The study was conducted at a single center and involved analyzing the use of diabetes technology, specifically continuous glucose monitors (CGMs) and automated insulin delivery (AID) systems, in adults with type 1 diabetes. The results showed that over the 8-year period, there were 15,903 clinic visits involving 4,174 unique patients. There was a significant increase in the use of both CGMs and AID systems, leading to an overall rise in diabetes technology utilization from 26.9% in 2014 to 82.7% in 2021. This increase in technology use was associated with a decrease in the average clinic-measured HbA1c levels, from 7.7% to 7.5%, and an increase in the percentage of adults achieving an HbA1c level below 7.0%, from 32.3% to 41.7%. Furthermore, the difference in HbA1c levels between individuals who used diabetes technology and those who did not became more pronounced over time, increasing from 0.36% in 2014 to 0.93% in 2021. In conclusion, the adoption of diabetes technology, including CGMs and AID systems, among adults with type 1 diabetes was linked to reduced HbA1c levels and an increased number of individuals achieving HbA1c levels below 7.0%.

CLINICAL STUDY

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY